The Wall Street Journal Recognizes Zargis Medical with Technology Innovation Award
September 11 2006 - 4:17PM
PR Newswire (US)
PRINCETON, N.J., Sept. 11 /PRNewswire-FirstCall/ -- Zargis Medical
Corp., a spin-off from Siemens Corporate Research (NYSE:SI) and a
majority-owned subsidiary of Speedus Corp. (NASDAQ:SPDE), today
announced that it was selected as a runner-up in The Wall Street
Journal's 2006 Technology Innovation Awards. The competition honors
breakthrough technologies from around the world in several
categories. As published in today's Wall Street Journal, Zargis was
selected as a runner-up in the Medical Devices category for
Cardioscan(R), the world's first computer-aided stethoscope that
aids physicians in identifying and evaluating murmurs and other
heart sounds that may be indicative of cardiovascular disease. In
selecting award winners, The Wall Street Journal's panel of judges
considered whether the submitted innovations represented
breakthroughs from conventional methods, rather than just
incremental improvements. "We are thrilled to have received this
recognition from The Wall Street Journal," stated Zargis CEO John
Kallassy. "Despite the fact that the stethoscope has long served as
a representative symbol of medicine, it has remained virtually
unchanged for almost two hundred years. By leveraging our
state-of-the-art technology to enhance and extend the clinical
usefulness of the stethoscope in ways never before imagined, Zargis
Medical has brought the age-old practice of assessing heart sounds
into the 21st century." About Zargis Medical Corp. Zargis Medical
Corp. develops advanced diagnostic decision support products and
services for primary care physicians, pediatricians, cardiologists
and other healthcare professionals. Zargis was formed in 2001 when
Siemens Corporate Research, a division of Siemens AG (NYSE:SI), and
Speedus Corp. co-invested to develop and market an advanced
acoustic technology designed to detect heart abnormalities
identified through analysis of heart sounds. About Cardioscan
Zargis has developed Cardioscan, the first and only FDA-authorized
computer-assisted medical device designed to support physicians in
analyzing heart sounds for the identification of suspected systolic
and diastolic murmurs. Cardioscan is a non-invasive device that is
easy to use, portable, and takes just minutes to perform. The
device implements voice-guided protocol and a graphical user
interface while maintaining an efficient physician workflow.
Cardioscan provides a summary of findings in terms that are readily
understood by physicians and offers an additional range of
quantitative auscultatory information that cannot be obtained
through listening alone. For additional information about Zargis or
Speedus Corp., visit the following Web sites:
http://www.zargis.com/ and http://www.speedus.com/. Statements
contained herein that are not historical facts, including but not
limited to statements about the Company's product, corporate
identity and focus, may be forward-looking statements that are
subject to a variety of risks and uncertainties. There are a number
of important factors that could cause actual results to differ
materially from those expressed in any forward- looking statements
made by the Company, including, but not limited to, the continuing
development of the Company's sales, marketing and support efforts.
DATASOURCE: Zargis Medical Corp. CONTACT: Peter Hodge,
1-888-773-3669, ext. 23, or , for Zargis Medical Corp. Web site:
http://www.speedus.com/ http://www.zargis.com/
Copyright
Speedus (CE) (USOTC:SPDE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Speedus (CE) (USOTC:SPDE)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Speedus Corp (CE) (OTCMarkets): 0 recent articles
More Speedus (MM) News Articles